A Axsome Therapeutics
| Market Cap | $8.62B |
| P/E Ratio | — |
| Forward P/E | 27.70 |
| Dividend Yield | — |
| Beta | 0.47 |
| 52W Range | $95.65 - $189.10 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Torray Funds Torray Investment Partners | 0.39% | $2.70M | 14,794 | Reduce 15.07% |
Insider Trading
| Insider Name of the company insider who made the trade 31 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Jacobson Mark L.Chief Operating Officer | Sale | 35,378 | $161.88 | $5.73M | 26 Feb 2026 | 27 Feb 2026 |
| Coleman Mark | Sale | 25,000 | $161.11 | $4.03M | 26 Feb 2026 | 27 Feb 2026 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 32,410 | $185.60 | $6.02M | 02 Feb 2026 | 02 Feb 2026 |
| Herriot TabuteauChief Executive Officer | Sale | 32,410 | $185.60 | $6.02M | 02 Feb 2026 | 02 Feb 2026 |
| Pizzie NickChief Financial Officer | Sale | 12,000 | $187.92 | $2.26M | 22 Jan 2026 | 23 Jan 2026 |
| Maizel AriChief Commercial Officer | Sale | 7,500 | $184.44 | $1.38M | 21 Jan 2026 | 23 Jan 2026 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 31,261 | $170.38 | $5.33M | 07 Jan 2026 | 07 Jan 2026 |
| Herriot TabuteauChief Executive Officer | Sale | 31,261 | $170.38 | $5.33M | 07 Jan 2026 | 07 Jan 2026 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 29,450 | $172.33 | $5.08M | 06 Jan 2026 | 07 Jan 2026 |
| Herriot TabuteauChief Executive Officer | Sale | 29,450 | $172.33 | $5.08M | 06 Jan 2026 | 07 Jan 2026 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 78,703 | $171.28 | $13.48M | 05 Jan 2026 | 07 Jan 2026 |
| Herriot TabuteauChief Executive Officer | Sale | 78,703 | $171.28 | $13.48M | 05 Jan 2026 | 07 Jan 2026 |
| Saad Mark E | Sale | 6,231 | $165.18 | $1.03M | 31 Dec 2025 | 02 Jan 2026 |
| Saad Mark E | Sale | 31,346 | $165.18 | $5.18M | 31 Dec 2025 | 02 Jan 2026 |
| Mark E SaadDirector | Sale | 31,346 | $165.18 | $5.18M | 31 Dec 2025 | 02 Jan 2026 |
| Mark E SaadDirector | Sale | 6,231 | $165.18 | $1.03M | 31 Dec 2025 | 02 Jan 2026 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 10,558 | $148.18 | $1.56M | 04 Dec 2025 | 04 Dec 2025 |
| Herriot TabuteauChief Executive Officer | Sale | 10,558 | $148.18 | $1.56M | 04 Dec 2025 | 04 Dec 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 20,163 | $146.94 | $2.96M | 03 Dec 2025 | 04 Dec 2025 |
| Herriot TabuteauChief Executive Officer | Sale | 20,163 | $146.94 | $2.96M | 03 Dec 2025 | 04 Dec 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 49,252 | $144.59 | $7.12M | 02 Dec 2025 | 04 Dec 2025 |
| Herriot TabuteauChief Executive Officer | Sale | 49,252 | $144.59 | $7.12M | 02 Dec 2025 | 04 Dec 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 21,775 | $134.49 | $2.93M | 05 Nov 2025 | 05 Nov 2025 |
| Herriot TabuteauChief Executive Officer | Sale | 21,775 | $134.49 | $2.93M | 05 Nov 2025 | 05 Nov 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 50,459 | $133.79 | $6.75M | 04 Nov 2025 | 05 Nov 2025 |
| Herriot TabuteauChief Executive Officer | Sale | 50,459 | $133.79 | $6.75M | 04 Nov 2025 | 05 Nov 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 91,705 | $132.34 | $12.14M | 03 Nov 2025 | 05 Nov 2025 |
| Herriot TabuteauChief Executive Officer | Sale | 91,705 | $132.34 | $12.14M | 03 Nov 2025 | 05 Nov 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 12,774 | $118.84 | $1.52M | 08 Oct 2025 | 08 Oct 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 13,390 | $118.77 | $1.59M | 07 Oct 2025 | 08 Oct 2025 |
| TABUTEAU HERRIOTChief Executive Officer | Sale | 19,220 | $120.17 | $2.31M | 06 Oct 2025 | 08 Oct 2025 |
Frequently Asked Questions
What is AXSM stock price today?
Axsome Therapeutics (AXSM) is currently trading at $168.51. The stock has a 52-week range of $95.65 to $189.10 and a market capitalization of $8.62B.
Is AXSM a good stock to buy in 2026?
Axsome Therapeutics has a P/E ratio of N/A (forward P/E: 27.7), a dividend yield of none, and 1-year performance of +56.2%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling AXSM stock?
There have been 31 insider transactions for AXSM in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has AXSM stock performed over the past year?
Axsome Therapeutics (AXSM) has returned +56.2% over the past 12 months. The stock traded between $95.65 and $189.10 during this period, and is currently at $168.51.
Which hedge funds own AXSM (Axsome Therapeutics)?
1 tracked hedge funds currently hold AXSM in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is AXSM's market cap and valuation?
Axsome Therapeutics (AXSM) has a market capitalization of $8.62B. The trailing P/E ratio is N/A and forward P/E is 27.7. The stock is classified in the Healthcare sector.
What is AXSM's revenue and profitability?
Axsome Therapeutics reported revenue of $638.50M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.47.
What sector is AXSM in and who are its biggest institutional holders?
Axsome Therapeutics (AXSM) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.